Business · 25/09/2023Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on Withdrawal of Hospira, Inc.'s Abbreviated New Drug Applications
Summary
The FDA has corrected a notice regarding the withdrawal of approval of eight abbreviated new drug applications, including one from Hospira, Inc., after receiving a timely request from Tolmar, Inc. to keep the approval in effect.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →